Toxicology and Pharmacokinetics of DT₃₈₈IL3, a Fusion Toxin Consisting of a Truncated Diphtheria Toxin (DT₃₈₈) Linked to Human Interleukin 3 (IL3), in Cynomolgus Monkeys

References

• Schiffer, C.A. (2001) "Acute myeloid leukemia in adults: where do we go from here?", Cancer Chemother. Pharmacol., 48\(Suppl. 1), S45 —S52.
   Google Scholar
• Burnett, A.K. (2001) "Evaluating the contribution of allogeneic and autologous transplantation to the management of acute myeloid leukemia in adults", Cancer Chemother. Pharmacol., 48\(Suppl. 1), S53—S58.
   Google Scholar
• Choc, S., Bennett, M.J., Fujii, G., Curmi, P.M.G., Kantardjieff, K.A., Collier, R.J., et al. (1992) "The crystal structure of diphtheria toxin", Nature, 357, 216–222.
   Google Scholar
• Brooke, J.S. and Cha, J.H. (2000) "Molecular characterization of key diphtheria toxin: receptor interactions", Biochem. Biophys. Res. Commun., 275, 374 — 381.
   Google Scholar
• Silverman, J.A., Mindell, J.A., Finkelstein, A., Shen, W.H. and Collier, R.J. (1994) "Mutational analysis of the helical hairpin region of diphtheria toxin transmembrane domain", J. Biol. Chem., 269, 22524–22532.
   Google Scholar
• Bodley, J.W., Dunlop, P.C. and Van Ness, B.G. (1984) "Diphtha-mide in elongation factor 2: ADP ribosylation, purification, and properties", Meth. Enzymol., 106, 378–387.
   Google Scholar
• vanderSpek, J.C. and Murphy, J.R. (2000) "Fusion protein toxins based on diphtheria toxin: selective targeting of growth factor receptors of eukaryotic cells", Meth Enzymol, 327, 239–249.
   Google Scholar
• Frankel, A.E., Ramage, J., Latimer, A., Feely, T., Delatte, S., Hall, P., et al. (1999) "High level synthesis and maximal purification of the recombinant diphtheria fusion toxin DTGM for phase I clinical trials", Prot. Exp. Purif., 16, 190–201.
   Google Scholar
• Frankel, A.E., Powell, B.L., Hall, P.D., Case, L.D. and Kreitman, R.J. (2002) "Phase I trial of a novel diphtheria toxin/GM-CSF fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia (AML)", ClM. Cancer Res., 8, 1004–1013.
   Google Scholar
• Frankel, A.E., Ramage, J., Gannaway, S., Kiser, M., Alexander, R., Kucera, G., et al. (2000) "Characterization of diphtheria fusion toxins targeted to the interleukin-3 receptor", Prot. Eng., 13, 575–581.
   Google Scholar
• Frankel, A.E., McCubrey, J., Miller, M.S., Delatte, S., Ramage, J., Kiser, M., et al. (2000) "Diphtheria toxin fused to human interleulcin-3 is toxic to blasts from patients with myeloid leukemias", Leukemia, 14, 576— 585.
   Google Scholar
• Suda, T., Suda, J., Ogawa, M. and Ihle, J.N. (1985) Permissive role of interleulcin 3 (IL-3) in proliferation and differentiation of multipotential hematopoietic progenitors in culture", J. Cell. Physiol., 124, 182–190.
   Google Scholar
• Ailles, L.E., Gerhard, B. and Hogge, D.E. (1997) "Detection and characterization of primitive malignant and normal prgenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytolcines", Blood, 90,2555–2564.
   Google Scholar
• Alexander, R.L., Ramage, J., Kucera, G.L., Caliguiri, M.A. and Frankel, A.E. (2001) "High affinity interleulcin-3 receptor expres-sion on blasts from patients with acute myelogenous leukemia (AML) correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein", Leuk. Res., 25, 875 — 881.
   Google Scholar
• Alexander, R.L., Kucera, G.L., Klein, B. and Frankel, A.E. (2000) "In vitro interleulcin-3 binding to leukemia cells predicts cytotoxi-city of a diphtheria toxin/1L3 fusion protein", Bioconj. Chem., 11, 564–568.
   Google Scholar
• Feuring-Buske, M., Frankel, A.E., Alexander, R.L., Gerhard, B. and Hogge, D.E. (2002) "A diphtheria toxin-interleulcin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors", Cancer Research, 62, 1730 —1736.
   Google Scholar
• Black, J.H., McCubrey, J.A., Willingham, MC., Ramage, J., Hogge, D.E. and Frankel, A.E. (2003) "Diphtheria toxin-inter-leulcin-3 fusion protein (DT388IL3) prolongs disease-free survival of leukemic immunocompromised mice", Leukemia, 17, 155–159.
   Google Scholar
• Uckun, F.M., Yanishevslci, Y., Turner, N., Waurzyniak, B., Messinger, Y., Chelstrom, L.M., et al. (1997) "Pharmacolcinetic features, immuongenecity, and toxicity of B43(anti-CD19)-poke-weed anitiviral protein immunotoxin in cynomolgus monkeys", Clin. Cancer Res., 3, 325–337.
   Google Scholar
• Hotchkiss, CE., Hall, P.D., Cline, J.M., Willingham, MC., Kreitman, R.J., Gardin, J., et al. (1999) "Toxicology and Pharmacolcinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony stimulating factor (GMCSF) in cynomolgus monkeys", Toxicol. Appl. Pharmacol., 158, 152–160.
   Google Scholar
• Hall, P.D., Virella, G., Willoughby, T., Atchley, D.H., Kreitman, R.J. and Frankel, A.E. (2001) "Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia", Clin. Immunol., 100(2), 191–197.
   Google Scholar
• van Gils, F.C., Budel, L.M., Burger, H., van Leen, R.W., Lowenberg, B. and Wagemaker, G. (1994) "Interleulcin -3 (IL-3) receptors on rhesus monkey bone marrow cells: species specificity of human IL-3, binding characteristics, and lack of competition with GM-CSF", Exp. Hematol., 22, 248–255.
   Google Scholar
• Van Gils, F.C., Mulder, A.H., van den Bos, C., Burger, H., van Leen, R.W. and Wagemaker, G. (1993) "Acute side effects of homologous interleulcin-3 in rhesus monkeys", Am. J. Pathol., 143, 1621–1633.
   Google Scholar
• Kiser, M., McCubrey, J.A., Steelman, L.S., Shelton, J.G., Ramage, J., Alexander, R.L., et al.. (2001) "Oncogene-dependent engraft-ment of human myeloid leukemia cells in immunosup-pressed mice", Leukemia, 15, 814 — 818.
   Google Scholar
• Cohen, K.A., Liu, T.F., Bissonette, R., Puri, R.K. and Frankel, A.E. (2003) "DAB389EGF fusion protein therapy of refractory glioblastoma multiforme", Curr. Pharm. Biotech., 4, 39–49.
   Google Scholar
• US Food and Drug Administration (2003) Product Approval Information—Licensing Action. www.fda.gov/cber/review/denser 020599r1.pdf.
   Google Scholar
• Wu, A., Yamada, K., Neville, D.M., Awwad, M., Wain, J.C., Shimizu, A., et al. (2003) "Xenogeneic thymus transplantation in a pig-to-baboon model", Transplantation, 75, 282–291.
   Google Scholar
• Mayer, P., Valent, P., Schmidt, G., Liehl, E. and Bettelheim, P. (1989) "The in vivo effects of recombinant human interleulcin-3: demonstrating basophil differentiation factor, histamine-producing activity, and priming of GM-CSF-responsive progenitors in nonhu-man primates", Blood, 74, 613–621.
   Google Scholar
• Vallera, D.A., Seo, S.Y., Panoskaltsis-Mortari, A., Griffin, J.D. and Blazar, B.R. (1999) "Targeting myeloid leukemia with a DT390-mIL-3 fusion immunotoxin: ex vivo and in vivo studies in mice", Protein Engineering, 12, 779–785.
   Google Scholar
• Korpelainen, El., Gamble, JR., Smith, W.B., Goodall, G.J., Qiyu, S., Woodcock, J.M., et al. (1993) "The receptor for interleulcin 3 is selectively induced in human endothelial cells by tumor necrosis factor a and potentiates interleulcin 8 secretion and neutrophil transmigration", Proc. Natl. Acad. Sci. USA, 90, 11137–11141.
   Google Scholar
• Dentelli, P., Del Sorbo, L., Rosso, A., Molinar, A., Garbarino, G., Camussi, G., et al. (1999) "Human IL-3 stimulates endothelial cell motility and promotes in vivo new vessel formation", J. Immunol., 163, 2151–2159.
   Google Scholar
• Tomblyn, M.R. and Tallman, M.S. (2003) "New developments in antibody therapy for acute myeloid leukemia", Semin. Oncol., 30, 502— 508.
   Google Scholar